Clinical trials: Lipid Disorders
Fat Disorder, Fat Redistribution
Effect of Tecartherapy in the Treatment of Localized Fat and Sagging Abdominal Skin - Clinical and Experimental Study
The excess of localized fat causes changes in the body contour and consequently changes in the properties of the skin and in the connective tissue, providing sagging skin.
- Trial name
- Tecarterapy (NCT05020054)
- Testing
- Tecartherapy Intervention
- Where
- Brazil
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Indústria Brasileira Equipamentos Médicos - IBRAMED
Cystic Fibrosis
Single Dose Escalation Study of TR02 (Sustained Lipid Inhalation Technology [SLIT™] Amikacin) in Participants With Cystic Fibrosis (CF) Having Chronic Infections of Pseudomonas Aeruginosa
The primary purpose of this study is to evaluate the safety and tolerability of three active doses of nebulized amikacin in a SLIT™ formulation.
- Trial name
- NCT06238856
- Testing
- SLIT™ Amikacin
- Volunteers
- 18 people
- Sponsor
- Insmed Incorporated
Lysosomal Acid Lipase Deficiency
Screening for Lysosomal Acid Lipase Deficiency
The primary outcome of this study is the development of a clinical profile of pediatric patients with LAL-D, which will enable the Sponsor to provide more focused guidance to the medical community as to which pediatric patients…
- Trial name
- NCT02926872
- Testing
- There is no intervention in the study
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Hypercholesterolemia
Study of Evinacumab (REGN1500) in Participants With Persistent Hypercholesterolemia
The primary objective of the study is to evaluate the reduction of LDL-C by evinacumab in comparison to placebo after 16 weeks in patients with primary hypercholesterolemia (HeFH, or non-HeFH with a history of clinical ASCVD)…
- Trial name
- NCT03175367
- Testing
- Evinacumab, Background Lipid Modifying Therapy (LMT)
- Where
- 95 sites in United States, Australia and 18 more
- Volunteers
- 272 people
- Sponsor
- Regeneron Pharmaceuticals
Hypertension, Hyperlipidemia
Bioequivalence Study of CJ-30061 in Healthy Male Volunteers
To compare the pharmacokinetics and safety after a single dose administration of CJ-30061 and co-administration of Exforge® 5/160mg, Lipitor® 20mg in healthy adult volunteers
- Trial name
- NCT03657472
- Testing
- CJ-30061, Exforge® 5/160mg & Lipitor® 20mg
- Where
- South Korea
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- HK inno.N Corporation
Coronary Heart Disease, Hypercholesterolemia
Compliance With LDL-Lowering Therapy (Study P05467)(COMPLETED)
This observational study is being conducted in patients receiving statin treatment as secondary prevention of coronary heart disease under the current standard of care in compliance with European guidelines.
- Conditions
- Coronary Heart Disease, Hypercholesterolemia, Hyperlipidemia
- Trial name
- NCT00723723
- Testing
- Statin
- Volunteers
- 555 people
- Sponsor
- Organon and Co
Hypertension, Dyslipidemia
Efficacy and Safety of Fluvastatin or Valsartan and Their Combination in Dyslipidemic Patients With Hypertension and Endothelial Dysfunction
Patients with mild to moderate hypertension, dyslipidemia (imbalanced blood lipids) and decreased vascular dilatation, receiving a cholesterol lowering diet were given either valsartan or fluvastatin for 8 weeks.
- Trial name
- NCT00171327
- Testing
- valsartan, fluvastatin
- Where
- Russia
- Volunteers
- 213 people
- Sponsor
- Novartis
Fabry Disease, Fabry´s Disease
The Efficacy and Safety of Switch Between Agalsidase Beta to Agalsidase Alfa for Enzyme Replacement in Patients With Anderson-Fabry Disease
The current approved treatment for Fabry disease is enzyme replacement therapy (ERT). There are actually 2 products in this therapeutic class available: Replagal® (agalsidase alfa) and Fabrazyme® (agalsidase beta).
- Conditions
- Fabry Disease, Fabry´s Disease, Anderson-Fabry Disease
- Trial name
- SWITCH (NCT01268241)
- Where
- 9 sites in Argentina, Belgium and 6 more
- Volunteers
- 200 people
- Sponsor
- CENTOGENE GmbH Rostock
Metabolic Syndrome
The Effect of Fluvastatin XL® Treatment in Patients With Metabolic Syndrome
This study evaluated safety, tolerability and efficacy of Fluvastatin XL® -extended release (80 mg once daily) in patients with metabolic syndrome
- Trial name
- NCT00664742
- Testing
- Fluvastatin XL®
- Where
- Turkey (Türkiye)
- Volunteers
- 614 people
- Sponsor
- Novartis
Primary Prevention of Atherosclerotic Cardiovascular Disease
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
CKJX839D12302 is a pivotal Phase III study designed to test the hypothesis that treatment with inclisiran sodium 300 milligram (mg) subcutaneous (s.c.) administered on Day 1, Day 90, and every 6 months thereafter in patients at…
- Trial name
- NCT05739383
- Testing
- Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
- Where
- 983 sites in United States, Argentina and 40 more
- Volunteers
- 14,012 people
- Sponsor
- Novartis Pharmaceuticals
Overweight, Elevated Cholesterol
Observational Study of Lyzme5 Impact on Cholesterol and Body Weight in Man
This observational placebo-controlled pilot study is intended to document whether or not Lyzme5, an over-the-counter (OTC) proprietary nutritional supplement product can positively impact, (a) weight and, (b) cholesterol levels…
- Trial name
- Lyzme5 (NCT01634646)
- Testing
- Lyzme5
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Jeff Golini
Type II Diabetes Mellitus, Dyslipidemia
Follow-On Study of Pitavastatin Versus Atorvastatin in Patients With Type II Diabetes Mellitus and Combined Dyslipidemia
This is a sixteen-week double-blind active-controlled follow-on and 28-week single-blind extension study for patients who participated in study NK-104-305.
- Trial name
- NCT00344370
- Testing
- Pitavastatin, Atorvastatin
- Where
- 35 sites in Denmark, Germany and 4 more
- Volunteers
- 214 people
- Sponsor
- Kowa Research Europe
Fabry Disease
Fabry Disease Registry & Pregnancy Sub-registry
The Fabry Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Fabry disease, irrespective of treatment status.
- Trial name
- NCT00196742
- Where
- 284 sites in United States, Argentina and 42 more
- Volunteers
- 9,000 people
- Sponsor
- Genzyme, a Sanofi Company
Hypercholesterolaemia
PULSAR - A Prospective Study to Evaluate the Utility of Low Doses of the Statins Atorvastatin and Rosuvastatin.
To compare reduction of LDL-C and safety between 10mg rosuvastatin and 20mg atorvastatin after 6 weeks treatment
- Trial name
- NCT00329173
- Testing
- Rosuvastatin, Atorvastatin
- Volunteers
- 1,000 people
- Sponsor
- AstraZeneca
Severe Hypertriglyceridemia
Epanova® Compared to Lovaza® In a Pharmacokinetic, Single-dose, Evaluation
The objectives of this study are to compare the relative bioavailabilities of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in plasma from a single dose of Epanova or Lovaza during periods of high- and low -fat…
- Trial name
- ECLIPSE (NCT01208961)
- Testing
- Epanova (4 g) and Lovaza (4 g), Lovaza (4 g) and Epanova (4 g)
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Hypertension, Hypercholesterolemia
Multicenter, Prospective, Non-interventional, Observational Study to Confirm the Long-term Efficacy and Safety of Rosuampin Tab. in Patients With Hypertension and Hypercholesterolemia
This study is to confirm the long-term efficacy and safety of Rosuampin Tab. in patients with hypertension and hypercholesterolemia
- Trial name
- NCT06293261
- Testing
- Rosuampin 5/5mg, 10/5mg, 20/5mg, 10/10mg
- Where
- 39 sites in South Korea
- Volunteers
- 5,047 people
- Sponsor
- Yuhan Corporation
Hyperlipidemia, Type 2 Diabetes
A Single Center Study to Evaluate the Efficacy and Safety of ETC 1002 in Subjects With Type 2 Diabetes
This Phase 2 study will asses the LDL-C lowering efficacy of ETC-1002 versus placebo in subjects with type 2 diabetes.
- Trial name
- NCT01607294
- Testing
- ETC-1002
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Esperion Therapeutics, Inc.
Hypercholesterolemia
A Study of Evacetrapib (LY2484595) in Japanese Participants With Primary Hypercholesterolemia
The main purpose of this study is to evaluate the efficacy and safety of the study drug known as evacetrapib in Japanese participants with primary hypercholesterolemia.
- Trial name
- NCT02260635
- Testing
- Evacetrapib
- Where
- 2 sites in Japan
- Volunteers
- 54 people
- Sponsor
- Eli Lilly and Company
Familial Hypercholesterolemia - Homozygous
Efficacy and Safety of Lomitapide in Japanese Patients With HoFH on Concurrent Lipid-Lowering Therapy
Study to Evaluate the Efficacy and Safety of Lomitapide in Japanese Patients with Homozygous Familial Hypercholesterolemia (HoFH) on Concurrent Lipid-Lowering Therapy.
- Trial name
- NCT02173158
- Testing
- lomitapide
- Where
- 6 sites in Japan
- Volunteers
- 9 people
- Sponsor
- Aegerion Pharmaceuticals, Inc.
Dyslipidemia, Hypertension
Crestor RUSH (The Efficacy of RosUvaStatin for Korean Dyslipidemia Patients With Hypertension )
To evaluate the efficacy of rosuvastatin in Korean dyslipidemia patients with hypertension.
- Trial name
- RUSH (NCT00526708)
- Where
- 3 sites in South Korea
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.